LabCorp strengthens nonclinical development portfolio with acquisition
LabCorp announced the closing of its acquisition of Toxikon Corporation in December of 2021. Toxicon Corporation specializes in testing and consulting services to bring full-service drugs and medical devices to market approval. Toxikon Corporations location in Bedford, Massachusetts not only provides a strategic footprint by enabling LabCorp access to clients in the Boston area, but also has capacity for expansion. The acquisition bolsters LabCorp’s nonclinical development portfolio, and with strategic access to pharmaceutical and biotechnology clientele in the Boston, Massachusetts area, has the opportunity to increase their market share in the segment.
COVID|Balance Sheet|Labor|New Activity|M&AIn response to volatile demand in the wake of the first COVID-19 surge, the company undertook a comprehensive cost reduction program, aimed at shoring up labor and supply costs.
Lorem Ipsum text header Report Title
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas non leo lacinia, consectetur ipsum non, pretium augue. Vestibulum accumsan dignissim massa, eu scelerisque mi malesuada ut. Aliquam scelerisque facilisis nisl ac varius. Nunc luctus nunc vel eros iaculis, vitae tristique ante fringilla. Ut vitae vulputate est, vel lacinia nisi. Curabitur eget nulla vitae mi faucibus imperdiet. Cras sagittis arcu eu diam pharetra iaculis eget sit amet risus. Morbi eget turpis ut diam commodo congue id eu lacus.
Cras sagittis arcu eu diam pharetra iaculis eget sit amet risus. Morbi eget turpis ut diam commodo congue id eu lacus.